Literature DB >> 6224769

Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.

G Panichi, A Pantosti, G P Testore.   

Abstract

Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa. A clinical study was conducted on forty hospitalized patients with bacteriologically proven urinary tract infections; 20 patients were given norfloxacin and 20 co-trimoxazole. Clinical results were excellent in both groups; norfloxacin was effective in infections due to Ps. aeruginosa and other multi-resistant pathogens. No side effects were reported.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6224769     DOI： 10.1093/jac/11.6.589

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 3.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

Review 4.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

5.  Norfloxacin penetration into human renal and prostatic tissues.

Authors:  M G Bergeron; M Thabet; R Roy; C Lessard; P Foucault
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

6.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography.

Authors:  A Weber; D Chaffin; A Smith; K E Opheim
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

Authors:  E J Goldstein; M L Alpert; B P Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.